Targeting Sensitive-Strain and Resistant-Strain Malaria Parasites Through a Metal-Based Approach

Recent Advances in the Biological Investigation of Organometallic Platinum-Group Metal (Ir, Ru, Rh, Os, Pd, Pt) Complexes as Antimalarial Agents

“…The activity of platinum complexes goes as far back as the 1960s with the epochal discovery of the anticancer activity of cis-diamminedichloridoplatinum(II), commonly known as cisplatin, by Rosenberg and co-workers [73]. Next generation platinum(II) derivatives (77)(78)(79), shown in Figure 20, have since been developed and approved to address the challenges faced by cisplatin (76), namely, limited selectivity, development of clinical resistance, and acute toxicity [74,75]. Numerous examples of inorganic platinum complexes possessing antiplasmodial activity have been reported in the literature.…”

“…Numerous examples of inorganic platinum complexes possessing antiplasmodial activity have been reported in the literature. Several reviews [ 19 , 76 , 77 ] and a published book chapter [ 78 ] give detailed accounts of antiplasmodial platinum-based complexes. Representative examples of inorganic platinum complexes 80 – 81 with antimalarial activity are also illustrated in Figure 21 [ 20 , 79 ].…”

Subcellular Localisation of a Quinoline‐Containing Fluorescent Cyclometallated IrIII Complex in Plasmodium falciparum

“…In this regard, recent emphasis has been placed upon organometallic derivatisation of known organic drugs [11,12] . It has been well documented that the conjugation of a transition metal to an organic drug with a known pharmacophore improves the biological activity of the compound as a whole [12–14] .…”

“…In this regard, recent emphasis has been placed upon organometallic derivatisation of known organic drugs [11,12] . It has been well documented that the conjugation of a transition metal to an organic drug with a known pharmacophore improves the biological activity of the compound as a whole [12–14] . The field of metal‐based drugs was pioneered by the discovery of the illustrious anticancer platinum‐containing drug, cisplatin, [15] and further evolved to the antimalarial drug‐candidate, ferroquine (FQ) [16–18] .…”

“…[11,12] It has been well documented that the conjugation of a transition metal to an organic drug with a known pharmacophore improves the biological activity of the compound as a whole. [12][13][14] The field of metal-based drugs was pioneered by the discovery of the illustrious anticancer platinum-containing drug, cisplatin, [15] and further evolved to the antimalarial drugcandidate, ferroquine (FQ). [16][17][18] This organometallic ferrocenyl analogue of CQ has shown great promise, particularly against chloroquine-resistant (CQR) strains of P. falciparum, in which it exhibits an activity 20-fold that of CQ itself.…”